What is Big Think?  

We are Big Idea Hunters…

We live in a time of information abundance, which far too many of us see as information overload. With the sum total of human knowledge, past and present, at our fingertips, we’re faced with a crisis of attention: which ideas should we engage with, and why? Big Think is an evolving roadmap to the best thinking on the planet — the ideas that can help you think flexibly and act decisively in a multivariate world.

A word about Big Ideas and Themes — The architecture of Big Think

Big ideas are lenses for envisioning the future. Every article and video on bigthink.com and on our learning platforms is based on an emerging “big idea” that is significant, widely relevant, and actionable. We’re sifting the noise for the questions and insights that have the power to change all of our lives, for decades to come. For example, reverse-engineering is a big idea in that the concept is increasingly useful across multiple disciplines, from education to nanotechnology.

Themes are the seven broad umbrellas under which we organize the hundreds of big ideas that populate Big Think. They include New World Order, Earth and Beyond, 21st Century Living, Going Mental, Extreme Biology, Power and Influence, and Inventing the Future.

Big Think Features:

12,000+ Expert Videos


Browse videos featuring experts across a wide range of disciplines, from personal health to business leadership to neuroscience.

Watch videos

World Renowned Bloggers


Big Think’s contributors offer expert analysis of the big ideas behind the news.

Go to blogs

Big Think Edge


Big Think’s Edge learning platform for career mentorship and professional development provides engaging and actionable courses delivered by the people who are shaping our future.

Find out more

Court's Gene Patent Decision Not Based on Biology

June 19, 2013, 11:55 AM

Editor's Note: This article appeared on RealClearScience, and is paired with another that disagrees. Read that article here.

The U.S. Supreme Court, in a unanimous 9-0 decision, determined that biotechnology companies are not allowed to patent genes. This is a step in the right direction, but the Court has not gone far enough.

Myriad Genetics, the company at the center of the case, had patented the DNA sequences of the BRCA1 and BRCA2 genes and devised a test to determine if a woman possesses versions of the genes linked to breast cancer. However, by “owning” the gene sequences, they effectively created a monopoly, preventing other companies from creating their own tests.

The Court ruled against this, claiming that a product of nature – in this case, a gene sequence – is not eligible to be patented. But, a synthetic version of the gene, known as complementary DNA (cDNA), is eligible. This sounds like a fair-minded compromise, but it could yet still prove greatly problematic for the scientific community.

Scattered within our genes are bits of rather mysterious DNA sequences called introns. Their purpose is largely unknown. To express a gene, a cell first converts the DNA sequence into messenger RNA (mRNA), but it snips out all the pesky introns. The pieces left over to make the RNA message provide the instructions necessary to synthesize proteins. If a team of scientists creates a DNA version of this protein-encoding mRNA, it is called cDNA and is eligible for patenting.

The trouble is that cDNA – while considered “synthetic” – is essentially nothing more than a simplified version of the same information already contained within the gene. The Court claimed “cDNA is patent eligible because it is not naturally occurring.” But this is scientifically dubious. True, cDNA itself isn’t found in nature, but the information is: It comes in the form of mRNA, which is abundant within a cell. In other words, there isn’t any novel, non-natural information in the cDNA.

Think of this analogy: A company that mines an ore, processes it, and extracts the pure metal is not allowed to patent the metal. Why? Because the metal is still a product of nature. “Simplifying” the ore by extracting the metal doesn’t make the metal patent eligible.

Even more troublesome for biologists is the fact that creating cDNA to study genes is extremely common in genetics laboratories. Therefore, if cDNA is patent eligible, it would suggest that studying the original gene is still largely off limits to those who don’t hold the patent. If that’s the case, then the Court’s decision hasn’t changed the status quo all that much.

What should be eligible for a patent? Any substantial change that produces a gene sequence that is not known to occur in nature should be patent eligible.

For example, non-natural mutations can be introduced into a gene sequence in order to study function; this often takes the form of DNA deletions and insertions, or in some cases, fusions with other genes. Other changes involve tweaking how the gene is expressed. Such manipulations should be patent eligible if a company decides to pursue that.

As a book author, I certainly recognize the necessity and value in protecting intellectual property. Without patents, technology simply would not progress.

Striking the proper balance between promoting innovation and allowing public access to scientific information is a delicate balancing act. Unfortunately, the Court has failed in this endeavor.

Alex B. Berezow is the editor of RealClearScience and co-author of Science Left Behind. He holds a PhD in microbiology.



Court's Gene Patent Decisio...

Newsletter: Share: